MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/jth.15187

Медицинская библиотека · Journal of thrombosis and haemostasis : JTH · 2021

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database.

Peyvandi Flora, Mahlangu Johnny N, Pipe Steven W, Hay Charles R M, Pierce Glenn F, Kuebler Peter, Kruse-Jarres Rebecca, Shima Midori

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

As the first non-factor replacement therapy for persons with congenital hemophilia A (PwcHA), emicizumab's safety profile is of particular interest to the community.

OBJECTIVES

We applied an algorithm for categorization of fatal events contemporaneous to emicizumab using reporter-assessed causality documented in the Roche Emicizumab Global Safety Database.

PATIENTS/

METHODS

All fatalities in PwcHA reported to the database (from clinical trials, pre-market access, and spontaneous post-marketing reports) were categorized into: associated with hemophilia A-hemorrhagic, thrombotic, human immunodeficiency virus (HIV)/hepatitis C virus (HCV), hepatic (non-HCV); associated with general population-trauma/suicide, non-HA-associated conditions; or, unspecified. Reported cause of death was not reassessed.

RESULTS

As of cut-off May 15, 2020, 31 fatalities in PwcHA taking emicizumab were reported. Median age at death was 58 years; 51% had factor VIII inhibitors. Fifteen fatalities were considered associated with HA; overall, the most frequent category was hemorrhage (11/31). Of these, six had a history of life-threatening bleeds, and four had a history of intracranial hemorrhage. The remaining HA-associated fatalities were related to HIV/HCV (3/31) and other hepatic causes (1/31). No cases were categorized as thrombotic. Of 10 cases considered not associated with HA, two were categorized as cardiovascular (non-thrombotic), five as infection/sepsis, and one each of trauma/suicide, pulmonary, and malignancy. Six cases were unspecified.

CONCLUSIONS

No unique risk of death was associated with emicizumab prophylaxis in PwcHA. The data reveal that mortality in PwcHA receiving emicizumab was primarily associated with hemorrhage or non-HA-associated conditions, and was not reported by treaters to be related to emicizumab treatment.

Для цитирования: Peyvandi Flora, Mahlangu Johnny N, Pipe Steven W, Hay Charles R M, Pierce Glenn F, Kuebler Peter, Kruse-Jarres Rebecca, Shima Midori. Application of a hemophilia mortality framework to the Emicizumab Global Safety Database.. Journal of thrombosis and haemostasis : JTH. 2021. DOI: 10.1111/jth.15187.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.